A further bispecific, humanized IgG1 antibody that is definitely underneath investigation is zenocutuzumab (MCLA-128), which acts by means of two unbiased mechanisms of motion: inhibition of HER2–HER3 signalling and elimination of tumour cells through ADCC. MCLA-128 functions by using a ‘dock and block’ system whereby one particular arm from the https://www.directivepublications.org/journal-of-clinical-breast-cancer/